Core 1: Pathology Core

核心1：病理学摘要/摘要 包括卵巢癌孢子应用的个别研究项目需要采购， 卵巢癌和卵巢良性肿瘤患者组织病理学资料的处理和分析 疾病。研究项目需要冰冻和福尔马林固定的石蜡包埋样本 肿瘤和正常组织。拟议的病理学核心加强了已经建立的MD Anderson 癌症中心妇科肿瘤库和P30赞助的MD Anderson癌症中心集中 具有支持数据库和内部网访问的组织存储库。核心通过以下方式提供组织获取 经验丰富的妇科病理学家，确保参与调查的研究人员获得高质量的组织 孢子以及其他孢子的调查人员。 病理核心的目标是提供冰冻组织、石蜡包埋组织和组织病理学 与组成本孢子提案的研究项目的具体需求有关的专业知识。要实现 这一目标，病理学核心提出了以下具体目标：目标1是保持冰冻的和 石蜡包埋的卵巢癌、良性卵巢突起和正常卵巢的组织库。这个 主要的组织来源将是提交给MD病理科的手术和活组织标本 安德森癌症中心。目标2是为所有临床标本提供病理复习 并在必要时提供组织病理学技术服务。这样的技术服务 包括免疫组织化学、原位杂交、创建特定组织微阵列载玻片、病理 小鼠肿瘤的评估和组织切片的显微解剖。目标3是建立血液/尿液/腹水 卵巢癌和良性卵巢突起手术患者的体液储存库。这些 体液将为检测推测的预后和诊断标记物提供资源 孢子项目中的实验。目标4是为所有人创建和维护一个相关的孢子数据库 病理科收集的样本。该孢子数据库将提供一个虚拟组织储存库 可与所有孢子调查人员以电子方式共享。

Core 1: Pathology SUMMARY/ ABSTRACT The individual research projects comprising this Ovarian Cancer SPORE application require the procurement, processing, and analysis of histopathological material from patients with ovarian cancer and benign ovarian diseases. The research projects have needs for frozen and formalin-fixed, paraffin-embedded samples of tumor and normal tissue. The proposed Pathology Core augments the already established MD Anderson Cancer Center Gynecological Tumor Bank and the P30-sponsored MD Anderson Cancer Center Centralized Tissue Repository with supporting database and intranet access. The Core provides for tissue acquisition by experienced gynecological pathologists to assure high-quality tissues for the investigators participating in this SPORE as well as investigators of other SPOREs. The goal of the Pathology Core is to provide frozen tissue, paraffin-embedded tissue, and histopathological expertise related to the specific needs of the research projects comprising this SPORE proposal. To achieve this goal, the Pathology Core proposes the following Specific Aims: Aim 1 is to maintain a frozen and paraffin-embedded tissue repository of ovarian cancer, benign ovarian processes, and normal ovary. The primary tissue source will be operative and biopsy specimens submitted to the Department of Pathology at MD Anderson Cancer Center. Aim 2 is to provide pathological review for all clinical specimens utilized in the SPORE projects and to provide histopathological technical services as necessary. Such technical services include immunohistochemistry, in situ hybridization, creation of specific tissue microarray slides, pathological evaluation of mouse tumors, and microdissection of tissue sections. Aim 3 is to establish a blood/urine/ascites fluid repository from patients undergoing surgery for ovarian cancer and benign ovarian processes. These fluids will provide the resources for the testing of putative prognostic and diagnostic markers derived from experiments in the SPORE projects. Aim 4 is to create and maintain a relational SPORE Database for all samples collected by the Pathology Core. This SPORE Database will provide for a virtual tissue repository that can be shared electronically with all SPORE investigators.